There are currently 11 vaccines with marketing authorisation with different number of serotypes (10 to 20) and different country reach (some are only authorised in one country, other in many). Of those 3 have WHO prequalification (PCV10-GSK, PCV13-PFZ, PCV10-SII).
Detailed information on the different products can be found in the comparison table
Once a PCV vaccination programme has been initiated, product switching is not generally recommended unless there are substantial changes in the epidemiological, programmatic, or financial situation that determined the original choice of product, e.g., an increasing burden of serotype 19A. Switching to another WHO-prequalified vaccine demonstrating similar immunogenicity to the currently used PCVs may be acceptable based on cost-saving considerations. If the series cannot be completed with the same vaccine, the available PCV product can be used. Restarting a series with a different PCV is not recommended, even for the primary series.
Available vaccines, licensing status, prequalification status, presentation, formulation, dosage and route of administration
